Inclusion Criteria:  - Subjects will be asked to participate leading up to the last Study #20-532 visit.  Subjects meeting the following criteria are eligible for study participation:  Provision of voluntary written informed consent by subject CARv3-TEAM-E T cells were administered in DF/HCC IRB Study #20-532 Able to comply with study requirements  Exclusion Criteria:  Subjects meeting the following criteria are to be excluded from study participation: Subject has disease progression AND has 2 consecutive VCN measurements at least 1 month apart, at least 6 months after drug product infusion where testing demonstrates undetectable VCN (<0.0003 vector copies per diploid genome) in peripheral blood cells. Withdrew consent to Study #20-532.